Banque Cantonale Vaudoise Raises Stake in Laboratory Co. of America Holdings (NYSE:LH)

Banque Cantonale Vaudoise raised its position in shares of Laboratory Co. of America Holdings (NYSE:LHFree Report) by 9.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,638 shares of the medical research company’s stock after buying an additional 551 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Laboratory Co. of America were worth $1,335,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LH. Eagle Bay Advisors LLC bought a new position in shares of Laboratory Co. of America during the second quarter valued at $29,000. Tradewinds Capital Management LLC bought a new position in shares of Laboratory Co. of America during the third quarter valued at $34,000. Exchange Traded Concepts LLC bought a new position in shares of Laboratory Co. of America during the third quarter valued at $37,000. ST Germain D J Co. Inc. bought a new position in shares of Laboratory Co. of America during the second quarter valued at $43,000. Finally, Oakworth Capital Inc. increased its holdings in shares of Laboratory Co. of America by 310.0% during the second quarter. Oakworth Capital Inc. now owns 246 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 186 shares in the last quarter. Hedge funds and other institutional investors own 89.37% of the company’s stock.

Insider Buying and Selling

In other Laboratory Co. of America news, CAO Peter J. Wilkinson sold 1,384 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $210.71, for a total transaction of $291,622.64. Following the transaction, the chief accounting officer now owns 2,087 shares in the company, valued at $439,751.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.65% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on LH shares. TheStreet upgraded Laboratory Co. of America from a “c+” rating to a “b-” rating in a report on Thursday, January 18th. JPMorgan Chase & Co. lifted their price objective on Laboratory Co. of America from $259.00 to $261.00 and gave the stock an “overweight” rating in a report on Friday, November 17th. Barclays initiated coverage on Laboratory Co. of America in a report on Wednesday, January 3rd. They issued an “equal weight” rating and a $222.00 price objective for the company. Finally, Mizuho cut their price target on Laboratory Co. of America from $257.00 to $230.00 and set a “buy” rating for the company in a research note on Tuesday, October 31st. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $242.00.

Get Our Latest Stock Analysis on LH

Laboratory Co. of America Stock Down 1.2 %

Shares of LH stock opened at $221.54 on Monday. The stock’s 50-day simple moving average is $222.77 and its 200-day simple moving average is $213.10. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.20 and a current ratio of 1.36. The firm has a market capitalization of $18.81 billion, a PE ratio of 29.62 and a beta of 1.04. Laboratory Co. of America Holdings has a fifty-two week low of $174.20 and a fifty-two week high of $234.09.

Laboratory Co. of America Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 13th. Investors of record on Tuesday, February 27th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.30%. The ex-dividend date is Monday, February 26th. Laboratory Co. of America’s dividend payout ratio (DPR) is 38.50%.

Laboratory Co. of America Profile

(Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.

Further Reading

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Co. of America Holdings (NYSE:LHFree Report).

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.